A Phase 2 interventional study of GSK1278863 and rhEPO in Anaemia, sponsored by GlaxoSmithKline. Completed at 123 sites in 15 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-10-12.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 2, and was the 6th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 9th largest by enrollment, is one of 3 that started in 2013, is one of 11 in phase 2, and was the 11th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be conducted in approximately 228 subjects with anemia associated with CKD who are not on dialysis. Two groups of subjects will be enrolled into the study: Group 1: recombinant human erythropoietin (rhEPO) naive subjects; Group 2: rhEPO users, who are currently receiving rhEPO. Subjects who are rhEPO naive will be randomized to receive either GSK1278863 once daily (QD) or rhEPO in a 3:1 fashion; subjects who are receiving an rhEPO before enrolling (rhEPO users) will be randomized in a 1:1 fashion to GSK1278863 QD or to the control arm. For those randomized to the control arm, the decision around whether the subject requires rhEPO, the selection of the type of rhEPO (if needed) and the choice of rhEPO dose to achieve and maintain Hgb concentrations within the target range should be based on Investigator clinical judgment, with the historical rhEPO dose and the current Hgb value being considered. The study consists of a screening phase of at least 4 weeks, a 24-week treatment phase and a follow-up visit that will occur approximately 4 weeks after completing treatment. It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
Drug: GSK1278863
All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
Drug: rhEPO
Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
Summary of Hemoglobin (Hgb) Concentration at Week 24
The original Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-10.0 g/dL (8.0-10.0 g/dL USA site only) and for Group 2- rhEPO users with a stable baseline Hgb of 9.0-10.5 g/dL (9.0-10.5 g/dL USA site only); the Hgb target range was 9.0 to 10.5 g/dL (9.0-10.5 g/dL USA site only). The study amended Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-11.0 g/dL and Group 2- rhEPO users with a stable baseline Hgb of 9.0-11.5 g/dL; Hgb target range - 10.0 to 11.5 g/dL. Data are presented for those participants following the original criteria ("Original") and those following the amended ("Amended") criteria. The primary objective was to characterize the ability of GSK1278863 to achieve mean Hgb response within the target range.
Time frame: Week 24
Number of Participants With Hemoglobin (Hgb) in the Target Range at Week 24
Target range is defined as: Original Hgb Criteria of 9.0 to 10.5 gram/deciliter (g/dL), and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
Time frame: Week 24
Number of Participants Reaching Pre-defined Hgb Stopping Criteria
The Hgb stopping criteria was a value of \<7.5 mg/dL obtained on-site via a validated point-of-care Hgb measurement device, which necessitated permanent discontinuation of the study medication. None of the participants met the stopping criteria therefore there is no data to present for this outcome measure.
Time frame: Over a period of 24 Weeks
Percent Change From Baseline in Hepcidin Concentration at Week 24
Baseline is the last pre-dose hepcidin value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the Week 24 value.
Time frame: Baseline and Week 24
Maximum Observed Change From Baseline in Serum Erythropoietin (EPO)
Blood samples for control arm were collected pre-dose for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-baseline values minus the Baseline value.
Time frame: Baseline to Week 24
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Blood samples for control arm were collected pre-dose for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for VEGF measurement. The maximum observed change from baseline in VEGF was recorded for each arm . Baseline value for VEGF is the pre-dose value on Day 1. Change from Baseline in VEGF was calculated as the individual post-baseline values minus the Baseline value.
Time frame: Baseline and up to Week 24
Percentage of Time Within, Below, and Above Hemoglobin (Hgb) Target Range, Between Weeks 12 and 24
The number of days a participant's Hgb was within target range was calculated by estimating (using linear interpolation) the number of days within target range between two scheduled Hgb visits. Percentage of time within range for a participant was calculated by dividing the total number of days that Hgb was within range during Weeks 12 to 24 by the total number of days the participant remained on treatment during Weeks 12 to 24. Similary, percent of time above and below Hgb target range was calculated. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
Time frame: Weeks 12 to 24
Change From Baseline in Ferritin Concentration at Week 24
Baseline is the last pre-dose ferritin value. Change was calculated by subtracting the Baseline value from the Week 24 value.
Time frame: Baseline and Week 24
Change From Baseline in Transferrin Concentration at Week 24
Baseline is the last pre-dose transferrin value. Change from Baseline in transferrin was calculated by subtracting the Baseline value from the Week 24 value.
Time frame: Baseline and Week 24
Percent Change From Baseline in Transferrin Saturation at Week 24
Transferrin saturation is measured as a percentage; it is a ratio of serum iron and total iron-binding capacity. Baseline is the last pre-dose transferrin saturation value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the post-dose value.
Time frame: Baseline and Week 24
Change From Baseline in Total Iron at Week 24
Baseline is the last pre-dose total iron value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.
Time frame: Baseline and Week 24
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 24
TIBC measures the blood's capacity to bind iron with transferrin. Baseline is the last pre-dose TIBC value. Change from Baseline in TIBC was calculated by subtracting the Baseline value from the Week 24 value.
Time frame: Baseline and Week 24
Change From Baseline in Reticulocyte Hemoglobin (CHr) at Week 24
Reticulocytes are slightly immature red blood cells. Reticulocyte Hgb content is used to differentiate iron deficiency from other causes of anemia. Baseline is the last pre-dose CHr value. Change from Baseline in reticulocyte Hgb was calculated by subtracting the Baseline value from the post-dose value.
Time frame: Baseline and Week 24
Change From Baseline in Hematocrit at Week 24
Baseline is the last pre-dose hematocrit value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.
Time frame: Baseline and Week 24
Change From Baseline in Red Blood Cell Count at Week 24
Baseline is the last pre-dose red blood cell count. Change from Baseline in red blood cell count was calculated by subtracting the Baseline count from the post-dose count.
Time frame: Baseline and Week 24
Change From Baseline in Reticulocyte Cell Count at Week 24
Reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline is the last pre-dose red reticulocyte count. Change from Baseline in reticulocyte cell count was calculated by subtracting the Baseline count from the Week 24 count.
Time frame: Baseline and Week 24
Concentration of GSK1278863 and Relevant Metabolites as a Population Pharmacokinetic Endpoint
Blood samples were collected for individual plasma GSK1278863 and metabolite (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, and GSK2531403) concentration measurement on Day 1 (pre-dose), Wk 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose). Participants available in each arm at the specified time points have been presented.
Time frame: Day 1 (pre-dose), Week (Wk) 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose)
Mean Number of Dose Adjustments up to 24 Weeks
After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system.
Time frame: From Week 4 up to 24 Weeks
Number of Participants With Dose Adjustments up to 24 Weeks, as a Measure of Dose Adjustment Frequency
After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. Frequency is presented as the number of participants with dose adjustment(s) once, twice, thrice, four times, or five times.
Time frame: From week 4 up to 24 weeks
Timing of Dose Adjustments at Weeks 4, 8, 12, 16, and 20
After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. The number of participants with an adjustment are presented at the timings at which adjustments were done.
Time frame: From Week 4 up to Week 20
Mean Total Cumulative Dose of GSK1278863 up to 24 Weeks
The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
Time frame: Up to 24 Weeks
Mean Final Dose of GSK1278863 up to 24 Weeks
The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
Time frame: Up to 24 Weeks
Number of Hemoglobin (Hgb) Excursions
A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. Hgb cycle is calculated as two consecutive Hgb excursions in different directions.
Time frame: Up to 24 Weeks.
Number of Hemoglobin (Hgb) Cycles up to 24 Weeks
A Hgb cycle is calculated as two consecutive Hgb excursions in different directions. A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.
Time frame: Up to 24 Weeks
Number of Dose Cycles up to 24 Weeks
A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease).
Time frame: Up to 24 weeks
Number of Participants With at Least One Hemoglobin (Hgb) Excursion up to 24 Weeks.
A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.
Time frame: Up to 24 weeks
Number of Participants With at Least One Hemoglobin (Hgb) Cycle up to 24 Weeks
A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. A Hgb cycle is two consecutive Hgb excursions in different directions.
Time frame: Up to 24 weeks
Number of Participants With at Least One Dose Cycle up to 24 Weeks
A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease). participants
Time frame: Up to 24 weeks
Number of Participants Receiving Additional Therapies of Blood Transfusions, Intravenous (IV) Iron or rhEPO at Any Time Post-Baseline
Participants receiving additional therapies of blood transfusions, intravenous (IV) iron or rhEPO any time Post Baseline were analyzed. RhEPO was not applicable for the control arms since it was a planned therapy in those arms, hence presented as NA. (EudraCT only: A value of 99999 is used where no data is available or NA.)
Time frame: From Day 1 up to Week 28
Number of Weeks Dose Withheld Because Hemoglobin (Hgb) Exceeded the Upper Limit
Number of Weeks dose was withheld because hemoglobin exceed the upper limit is presented as the number of participants with withheld dose during the time periods categorized by Weeks.
Time frame: From Week 4 up to Week 24
Two groups of participants(par.) were enrolled in this study. Group 1 consisted of recombinant human erythropoietin(rhEPO)-naive par. whereas Group 2 consisted of rhEPO users.
| Milestone | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Started | 136 | 44 | 36 | 36 |
| Completed | 116 | 41 | 32 | 33 |
| Not completed | 20 | 3 | 4 | 3 |
| Withdrew: Adverse event | 7 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 1 | 0 | 0 |
| Withdrew: Reached defined stopping criteria | 2 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 1 | 1 | 1 |
The original Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-10.0 g/dL (8.0-10.0 g/dL USA site only) and for Group 2- rhEPO users with a stable baseline Hgb of 9.0-10.5 g/dL (9.0-10.5 g/dL USA site only); the Hgb target range was 9.0 to 10.5 g/dL (9.0-10.5 g/dL USA site only). The study amended Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-11.0 g/dL and Group 2- rhEPO users with a stable baseline Hgb of 9.0-11.5 g/dL; Hgb target range - 10.0 to 11.5 g/dL. Data are presented for those participants following the original criteria ("Original") and those following the amended ("Amended") criteria. The primary objective was to characterize the ability of GSK1278863 to achieve mean Hgb response within the target range.
| grams per deciliter | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Original n=45,15,19,13 | 10.20 ± 0.906 | 10.64 ± 0.664 | 10.03 ± 0.522 | 10.66 ± 0.620 |
| Amended n=61,21,11,17 | 10.96 ± 1.044 | 11.05 ± 1.144 | 10.42 ± 0.827 | 10.86 ± 1.182 |
Target range is defined as: Original Hgb Criteria of 9.0 to 10.5 gram/deciliter (g/dL), and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
| participants | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Number of Participants With Hemoglobin (Hgb) in the Target Range at Week 24 | 78 | 20 | 22 | 19 |
The Hgb stopping criteria was a value of \<7.5 mg/dL obtained on-site via a validated point-of-care Hgb measurement device, which necessitated permanent discontinuation of the study medication. None of the participants met the stopping criteria therefore there is no data to present for this outcome measure.
| Participants | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Number of Participants Reaching Pre-defined Hgb Stopping Criteria | 0 | 0 | 0 | 0 |
Baseline is the last pre-dose hepcidin value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the Week 24 value.
| percent change in Hepcidin | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Percent Change From Baseline in Hepcidin Concentration at Week 24 | -19.27 (-28.10 to -9.36) | 6.67 (-13.62 to 31.72) | -9.87 (-28.59 to 13.76) | -17.12 (-33.22 to 2.86) |
Blood samples for control arm were collected pre-dose for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-baseline values minus the Baseline value.
| International Units per liter | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Maximum Observed Change From Baseline in Serum Erythropoietin (EPO) | 7.27 ± 12.744 | 27.05 ± 94.999 | 3.69 ± 20.554 | 25.85 ± 38.890 |
Blood samples for control arm were collected pre-dose for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for VEGF measurement. The maximum observed change from baseline in VEGF was recorded for each arm . Baseline value for VEGF is the pre-dose value on Day 1. Change from Baseline in VEGF was calculated as the individual post-baseline values minus the Baseline value.
| percent change in VEGF concentration | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF) | 76.36 (59.46 to 95.06) | 26.84 (1.73 to 58.15) | 49.99 (28.28 to 75.39) | 40.85 (19.14 to 66.52) |
The number of days a participant's Hgb was within target range was calculated by estimating (using linear interpolation) the number of days within target range between two scheduled Hgb visits. Percentage of time within range for a participant was calculated by dividing the total number of days that Hgb was within range during Weeks 12 to 24 by the total number of days the participant remained on treatment during Weeks 12 to 24. Similary, percent of time above and below Hgb target range was calculated. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
| percentage of days | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Percentage of time within target range | 68.99 ± 34.612 | 51.01 ± 41.403 | 75.06 ± 32.485 | 61.29 ± 43.352 |
| Percentage of time above target range | 22.84 ± 33.825 | 45.10 ± 42.579 | 17.96 ± 28.809 | 31.10 ± 41.683 |
| Percentage of time below target range | 8.17 ± 20.301 | 3.89 ± 16.175 | 6.98 ± 21.118 | 7.61 ± 25.113 |
Baseline is the last pre-dose ferritin value. Change was calculated by subtracting the Baseline value from the Week 24 value.
| micrograms per liter | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Ferritin Concentration at Week 24 | -30.8 ± 110.50 | -2.4 ± 77.06 | -63.4 ± 141.93 | -20.4 ± 63.38 |
Baseline is the last pre-dose transferrin value. Change from Baseline in transferrin was calculated by subtracting the Baseline value from the Week 24 value.
| grams per liter | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Transferrin Concentration at Week 24 | 0.077 ± 0.3577 | -0.008 ± 0.2694 | 0.171 ± 0.4124 | 0.018 ± 0.2395 |
Transferrin saturation is measured as a percentage; it is a ratio of serum iron and total iron-binding capacity. Baseline is the last pre-dose transferrin saturation value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the post-dose value.
| percent change | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Percent Change From Baseline in Transferrin Saturation at Week 24 | -1.1 (-8.0 to 6.4) | 12.3 (2.2 to 23.3) | -15.7 (-26.8 to -3.0) | 11.4 (-14.7 to 45.6) |
Baseline is the last pre-dose total iron value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.
| micromoles per liter | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Total Iron at Week 24 | 1.0 ± 5.01 | 2.5 ± 5.98 | -1.8 ± 5.54 | 0.7 ± 8.36 |
TIBC measures the blood's capacity to bind iron with transferrin. Baseline is the last pre-dose TIBC value. Change from Baseline in TIBC was calculated by subtracting the Baseline value from the Week 24 value.
| micromoles per liter | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 24 | 3.2 ± 6.46 | 0.1 ± 5.17 | 3.0 ± 9.44 | -1.0 ± 6.69 |
Reticulocytes are slightly immature red blood cells. Reticulocyte Hgb content is used to differentiate iron deficiency from other causes of anemia. Baseline is the last pre-dose CHr value. Change from Baseline in reticulocyte Hgb was calculated by subtracting the Baseline value from the post-dose value.
| picogram | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Reticulocyte Hemoglobin (CHr) at Week 24 | -0.19 ± 1.109 | -0.33 ± 1.085 | -0.32 ± 0.864 | -0.19 ± 1.546 |
Baseline is the last pre-dose hematocrit value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.
| percentage change in Fraction of 1 | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Hematocrit at Week 24 | 2.64 ± 3.389 | 3.13 ± 3.245 | -0.66 ± 3.074 | 2.09 ± 3.243 |
Baseline is the last pre-dose red blood cell count. Change from Baseline in red blood cell count was calculated by subtracting the Baseline count from the post-dose count.
| 10^12 cells per liter | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Red Blood Cell Count at Week 24 | 0.28 ± 0.377 | 0.34 ± 0.365 | -0.08 ± 0.312 | 0.22 ± 0.318 |
Reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline is the last pre-dose red reticulocyte count. Change from Baseline in reticulocyte cell count was calculated by subtracting the Baseline count from the Week 24 count.
| percentage of reticulocytes | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Change From Baseline in Reticulocyte Cell Count at Week 24 | -0.02 ± 0.551 | -0.12 ± 0.648 | 0.27 ± 0.892 | -0.09 ± 0.755 |
Blood samples were collected for individual plasma GSK1278863 and metabolite (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, and GSK2531403) concentration measurement on Day 1 (pre-dose), Wk 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose). Participants available in each arm at the specified time points have been presented.
| nanograms per milliliter | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| GSK1278863, Day 1, Pre-Dose, n=128, 35 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK1278863, Wk 4, 6-12 hour Post-Dose, n=116, 31 | 2.0 ± 5.18 | 1.1 ± 1.69 |
| GSK1278863, Wk 4, 7-13 hour Post-Dose, n=117, 31 | 2.3 ± 7.06 | 0.8 ± 1.22 |
| GSK1278863, Wk 4, 8-14 hour Post-Dose, n=116, 31 | 1.6 ± 4.93 | 1.6 ± 5.49 |
| GSK1278863, Wk 4, 9-15 hour Post-Dose, n=116, 31 | 1.4 ± 4.52 | 1.6 ± 4.60 |
| GSK1278863, Wk 20, Pre-Dose, n=111, 29 | 0.6 ± 3.07 | 0.3 ± 0.92 |
| GSK1278863, Wk 20, 1 hour Post-Dose, n=110, 28 | 22.8 ± 35.93 | 19.8 ± 19.66 |
| GSK1278863, Wk 20, 2 hour Post-Dose, n=109, 29 | 17.0 ± 28.57 | 19.4 ± 21.92 |
| GSK1278863, Wk 20, 3 hour Post-Dose, n=109, 29 | 11.6 ± 19.56 | 13.9 ± 19.12 |
| GSK2391220, Day 1, Pre-Dose, n=128, 35 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2391220, Wk 4, 6-12 hour Post-Dose, n=116, 31 | 3.2 ± 5.21 | 3.7 ± 2.89 |
| GSK2391220, Wk 4, 7-13 hour Post-Dose, n=117, 31 | 3.1 ± 5.67 | 3.2 ± 2.43 |
| GSK2391220, Wk 4, 8-14 hour Post-Dose, n=116, 31 | 2.8 ± 5.01 | 2.9 ± 2.54 |
| GSK2391220, Wk 4, 9-15 hour Post-Dose, n=116, 31 | 2.6 ± 4.89 | 3.1 ± 2.76 |
| GSK2391220, Wk 20, Pre-Dose, n=111, 29 | 1.0 ± 2.06 | 0.8 ± 0.98 |
| GSK2391220, Wk 20, 1 hour Post-Dose, n=110, 28 | 2.1 ± 3.52 | 1.6 ± 1.39 |
| GSK2391220, Wk 20, 2 hour Post-Dose, n=109, 29 | 3.8 ± 5.08 | 3.7 ± 2.98 |
| GSK2391220, Wk 20, 3 hour Post-Dose, n=109, 29 | 4.5 ± 5.43 | 4.7 ± 3.53 |
| GSK2487818, Day 1, Pre-Dose, n=128, 35 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2487818, Wk 4, 6-12 hour Post-Dose, n=116, 31 | 1.2 ± 3.87 | 1.0 ± 0.96 |
| GSK2487818, Wk 4, 7-13 hour Post-Dose, n=116, 31 | 1.1 ± 4.11 | 0.7 ± 0.70 |
| GSK2487818, Wk 4, 8-14 hour Post-Dose, n=116, 31 | 1.0 ± 4.48 | 0.6 ± 0.66 |
| GSK2487818, Wk 4, 9-15 hour Post-Dose, n=116, 31 | 0.9 ± 4.09 | 0.8 ± 1.16 |
| GSK2487818, Wk 20, Pre-Dose, n=111, 29 | 0.2 ± 0.56 | 0.1 ± 0.31 |
| GSK2487818, Wk 20, 1 hour Post-Dose, n=110, 28 | 1.4 ± 3.07 | 1.0 ± 1.09 |
| GSK2487818, Wk 20, 2 hour Post-Dose, n=109, 29 | 2.8 ± 4.28 | 2.7 ± 2.21 |
| GSK2487818, Wk 20, 3 hour Post-Dose, n=109, 29 | 3.1 ± 4.07 | 3.1 ± 2.56 |
| GSK2506102, Day 1, Pre-Dose, n=128, 35 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2506102, Wk 4, 6-12 hour Post-Dose, n=116, 31 | 1.0 ± 1.30 | 1.2 ± 0.65 |
| GSK2506102, Wk 4, 7-13 hour Post-Dose, n=117, 31 | 1.0 ± 1.51 | 1.1 ± 0.61 |
| GSK2506102, Wk 4, 8-14 hour Post-Dose, n=116, 31 | 0.9 ± 1.19 | 1.0 ± 0.61 |
| GSK2506102, Wk 4, 9-15 hour Post-Dose, n=116, 31 | 0.9 ± 1.29 | 1.1 ± 0.69 |
| GSK2506102, Wk 20, Pre-Dose, n=111, 29 | 0.4 ± 0.73 | 0.4 ± 0.42 |
| GSK2506102, Wk 20, 1 hour Post-Dose, n=110, 28 | 0.6 ± 0.88 | 0.5 ± 0.40 |
| GSK2506102, Wk 20, 2 hour Post-Dose, n=109, 29 | 0.9 ± 1.15 | 1.0 ± 0.71 |
| GSK2506102, Wk 20, 3 hour Post-Dose, n=109, 29 | 1.1 ± 1.25 | 1.2 ± 0.88 |
| GSK2531398, Day 1, Pre-Dose, n=128, 35 | 0.0 ± 0.01 | 0.0 ± 0.00 |
| GSK2531398, Wk 4, 6-12 hour Post-Dose, n=116, 31 | 1.3 ± 2.06 | 1.4 ± 1.08 |
| GSK2531398, Wk 4, 7-13 hour Post-Dose, n=117, 31 | 1.2 ± 2.50 | 1.2 ± 0.99 |
| GSK2531398, Wk 4, 8-14 hour Post-Dose, n=116, 31 | 1.1 ± 2.01 | 1.1 ± 0.93 |
| GSK2531398, Wk 4, 9-15 hour Post-Dose, n=116, 31 | 1.0 ± 2.10 | 1.2 ± 1.12 |
| GSK2531398, Wk 20, Pre-Dose, n=111, 29 | 0.3 ± 0.87 | 0.3 ± 0.38 |
| GSK2531398, Wk 20, 1 hour Post-Dose, n=110, 28 | 0.8 ± 1.53 | 0.6 ± 0.54 |
| GSK2531398, Wk 20, 2 hour Post-Dose, n=109, 29 | 1.6 ± 2.31 | 1.5 ± 1.22 |
| GSK2531398, Wk 20, 3 hour Post-Dose, n=109, 29 | 2.0 ± 2.42 | 2.0 ± 1.57 |
| GSK2531401, Day 1, Pre-Dose, n=128, 35 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2531401, Wk 4, 6-12 hour Post-Dose, n=116, 31 | 2.8 ± 4.00 | 4.3 ± 2.55 |
| GSK2531401, Wk 4, 7-13 hour Post-Dose, n=117, 31 | 2.7 ± 3.58 | 4.0 ± 2.29 |
| GSK2531401, Wk 4, 8-14 hour Post-Dose, n=116, 31 | 2.7 ± 3.74 | 3.8 ± 2.31 |
| GSK2531401, Wk 4, 9-15 hour Post-Dose, n=116, 31 | 2.5 ± 3.53 | 3.8 ± 2.29 |
| GSK2531401, Wk 20, Pre-Dose, n=111, 29 | 1.3 ± 2.41 | 1.4 ± 1.38 |
| GSK2531401, Wk 20, 1 hour Post-Dose, n=110, 28 | 1.6 ± 2.65 | 1.6 ± 1.29 |
| GSK2531401, Wk 20, 2 hour Post-Dose, n=109, 29 | 2.3 ± 3.14 | 2.5 ± 1.85 |
| GSK2531401, Wk 20, 3 hour Post-Dose, n=109, 29 | 2.8 ± 3.50 | 3.2 ± 2.22 |
| GSK2531403, Day 1, Pre-Dose, n=128, 35 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| GSK2531403, Wk 4, 6-12 hour Post-Dose, n=116, 31 | 3.7 ± 5.43 | 4.5 ± 3.14 |
| GSK2531403, Wk 4, 7-13 hour Post-Dose, n=117, 31 | 3.5 ± 5.27 | 3.9 ± 2.56 |
| GSK2531403, Wk 4, 8-14 hour Post-Dose, n=116, 31 | 3.4 ± 5.68 | 3.7 ± 2.72 |
| GSK2531403, Wk 4, 9-15 hour Post-Dose, n=116, 31 | 3.2 ± 5.42 | 3.8 ± 3.01 |
| GSK2531403, Wk 20, Pre-Dose, n=111, 29 | 1.4 ± 2.65 | 1.2 ± 1.25 |
| GSK2531403, Wk 20, 1 hour Post-Dose, n=110, 28 | 2.3 ± 3.69 | 1.9 ± 1.38 |
| GSK2531403, Wk 20, 2 hour Post-Dose, n=109, 29 | 3.9 ± 5.03 | 3.8 ± 2.95 |
| GSK2531403, Wk 20, 3 hour Post-Dose, n=109, 29 | 4.7 ± 5.43 | 4.9 ± 3.75 |
After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system.
| number of adjustments | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| Mean Number of Dose Adjustments up to 24 Weeks | 1.8 ± 0.82 | 1.7 ± 0.72 |
After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. Frequency is presented as the number of participants with dose adjustment(s) once, twice, thrice, four times, or five times.
| participants | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| Once | 39 | 11 |
| Twice | 50 | 11 |
| Thrice | 8 | 4 |
| Four times | 4 | 0 |
| Five times or more | 1 | 0 |
After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. The number of participants with an adjustment are presented at the timings at which adjustments were done.
| Participants | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| Week 4 | 78 | 21 |
| Week 8 | 24 | 6 |
| Week 12 | 30 | 7 |
| Week 16 | 30 | 6 |
| Week 20 | 22 | 5 |
The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
| milligrams | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| Mean Total Cumulative Dose of GSK1278863 up to 24 Weeks | 249.75 ± 186.921 | 320.42 ± 214.865 |
The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.
| milligrams per day | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| Mean Final Dose of GSK1278863 up to 24 Weeks | 1.75 ± 1.809 | 1.86 ± 1.692 |
A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. Hgb cycle is calculated as two consecutive Hgb excursions in different directions.
| number of excursions | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Number of Hemoglobin (Hgb) Excursions | 26 | 10 | 4 | 9 |
A Hgb cycle is calculated as two consecutive Hgb excursions in different directions. A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.
| number of Hgb cycles | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Number of Hemoglobin (Hgb) Cycles up to 24 Weeks | 3 | — | — | — |
A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease).
| number | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| Number of Dose Cycles up to 24 Weeks | 1 | — |
A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.
| participants | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Number of Participants With at Least One Hemoglobin (Hgb) Excursion up to 24 Weeks. | 23 | 10 | 4 | 8 |
A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. A Hgb cycle is two consecutive Hgb excursions in different directions.
| participants | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Number of Participants With at Least One Hemoglobin (Hgb) Cycle up to 24 Weeks | 3 | 0 | 0 | 0 |
A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease). participants
| participants | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| Number of Participants With at Least One Dose Cycle up to 24 Weeks | 1 | 0 |
Participants receiving additional therapies of blood transfusions, intravenous (IV) iron or rhEPO any time Post Baseline were analyzed. RhEPO was not applicable for the control arms since it was a planned therapy in those arms, hence presented as NA. (EudraCT only: A value of 99999 is used where no data is available or NA.)
| participants | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| Blood Transfusions | 3 | 1 | 1 | 0 |
| IV Iron | 20 | 3 | 3 | 4 |
| Inadvertent rhEPO use | 4 | NA | 9 | NA |
| Rescue rhEPO | 1 | NA | 0 | NA |
Number of Weeks dose was withheld because hemoglobin exceed the upper limit is presented as the number of participants with withheld dose during the time periods categorized by Weeks.
| participants | rhEPO-Naive GSK1278863 | rhEPO-User GSK1278863 |
|---|---|---|
| 0 Weeks | 102 | 30 |
| >0-4 Weeks | 4 | 2 |
| >4-8 Weeks | 8 | 0 |
| >8-12 Weeks | 8 | 0 |
| >12 Weeks | 1 | 0 |
Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from the start of study treatment until the follow-up contact (up to 28 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rhEPO-Naive GSK1278863 | — | 23/134 (17.2%) | 47/134 (35.1%) |
| rhEPO-Naive Control | — | 7/45 (15.6%) | 14/45 (31.1%) |
| rhEPO-User GSK1278863 | — | 7/36 (19.4%) | 20/36 (55.6%) |
| rhEPO-User Control | — | 7/35 (20%) | 13/35 (37.1%) |
| Event | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| ANY EVENTRenal and urinary disorders | 2/134 | 3/45 | 2/36 | 3/35 |
| ANY EVENTInfections and infestations | 2/134 | 3/45 | 1/36 | 1/35 |
| RENAL FAILURE CHRONICRenal and urinary disorders | 2/134 | 2/45 | 1/36 | 1/35 |
| ANY EVENTCardiac disorders | 4/134 | 1/45 | 0/36 | 1/35 |
| RENAL FAILURERenal and urinary disorders | 0/134 | 0/45 | 0/36 | 1/35 |
| RENAL IMPAIRMENTRenal and urinary disorders | 0/134 | 0/45 | 0/36 | 1/35 |
| PNEUMONIA PNEUMOCOCCALInfections and infestations | 0/134 | 0/45 | 0/36 | 1/35 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 1/134 | 0/45 | 0/36 | 1/35 |
| ANY EVENTGastrointestinal disorders | 1/134 | 0/45 | 1/36 | 1/35 |
| RECTAL HAEMORRHAGEGastrointestinal disorders | 0/134 | 0/45 | 0/36 | 1/35 |
| Event | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control |
|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 15/134 | 2/45 | 7/36 | 2/35 |
| DIARRHOEAGastrointestinal disorders | 10/134 | 0/45 | 0/36 | 6/35 |
| HYPERTENSIONVascular disorders | 2/134 | 1/45 | 4/36 | 1/35 |
| PRURITUSSkin and subcutaneous tissue disorders | 0/134 | 4/45 | 0/36 | 0/35 |
| BRONCHITISInfections and infestations | 2/134 | 1/45 | 0/36 | 3/35 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 2/134 | 2/45 | 1/36 | 3/35 |
| OEDEMA PERIPHERALGeneral disorders | 5/134 | 0/45 | 2/36 | 3/35 |
| AnaemiaBlood and lymphatic system disorders | 0/134 | 1/45 | 3/36 | 0/35 |
| AstheniaGeneral disorders | 1/134 | 3/45 | 1/36 | 0/35 |
| NAUSEAGastrointestinal disorders | 8/134 | 1/45 | 1/36 | 0/35 |
252 participants were randomized however the Baseline measurements are provided for the Intent-to-Treat (ITT) population (235 participants), which consisted of all randomized participants who received at least one dose of study drug, had a Baseline and at least one corresponding on-treatment assessment.
| Age, Continuous(Years) | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control | Total |
|---|---|---|---|---|---|
| Mean | 67.6 ± 12.21 | 64.3 ± 14.22 | 62.0 ± 14.06 | 66.7 ± 12.89 | 66.1 ± 13.04 |
| Sex: Female, Male(Participants) | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control | Total |
|---|---|---|---|---|---|
| Female | 75 | 23 | 17 | 23 | 138 |
| Male | 48 | 20 | 16 | 13 | 97 |
| Race/Ethnicity, Customized(Participants) | rhEPO-Naive GSK1278863 | rhEPO-Naive Control | rhEPO-User GSK1278863 | rhEPO-User Control | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 14 | 2 | 2 | 4 | 22 |
| Central/South Asian Heritage | 0 | 0 | 0 | 1 | 1 |
| Japanese/East Asian/South East Asian Heritage | 28 | 11 | 9 | 12 | 60 |
| White | 81 | 30 | 22 | 19 | 152 |
Showing the first 100 of 123 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2013, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863